US FDA Commissioner Race: Transparency Comes To Forefront With Study Of Refuse-To-File Letters
Executive Summary
Of the two main contenders to lead FDA, Josh Sharfstein is seen as much more likely to open up review decisions to public scrutiny, while Janet Woodcock might be a vote for the status quo and more deferential to industry concerns.